Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
... 16 /PRNewswire/ -- An innovative treatment for
infections of
the respiratory tract in cystic fibrosis ... cepacia pathogens
that can cause lethal
infections in cystic fibrosis patients. For Axentis
Pharma ... of
tobramycin and an innovative treatment for
infections of the respiratory
tract in patients with cystic ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... regimen. AIDS-associated opportunistic
infections and conditions were observed infrequently and sporadically.
infections involving the upper and lower respiratory tract were the only other
infections or adverse events that occurred in 5 percent or ...
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
... as a potential treatment for serious bacterial
infections in hospitalized patients.
The multi-center, ... incidence of serious and life-threatening
infections caused by resistant gram-negative bacteria and ... option for the treatment of life-threatening
infections caused by gram-negative bacteria."
About ...
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... in patients with active tuberculosis, severe
infections such as sepsis, opportunistic infections, in ... invasive fungal and other opportunistic
infections have been observed with the use of TNF antagonists including SIMPONI. Some of these
infections have been fatal. SIMPONI should not be given to ...
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
... for Once-Daily Treatment of Pseudomonas Lung
infections
MONMOUTH JUNCTION, N.J., June 25 ... antibiotic that aims to treat Pseudomonas lung
infections in cystic fibrosis (CF) and non-CF bronchiectasis ... trial in U.S. CF patients with Pseudomonas lung
infections and a preclinical study. The company also ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
... and SIMPONI 100 mg groups, respectively. Serious
infections were reported in 3 percent, 3 percent and 1 ... to fight infections. There are reports of serious
infections caused by bacteria, fungi, or viruses that have ... (TB) and histoplasmosis. Some of these
infections have been fatal. Your doctor will test you for TB ...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
... to fight infections. There are reports of serious
infections caused by bacteria, fungi, or viruses that have ... (TB) and histoplasmosis. Some of these
infections have been fatal. Your doctor will test you for TB ... Valleys and the Southwest) where certain fungal
infections like histoplasmosis or coccidioidomycosis are ...
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
... of severe complicated skin and skin structure
infections (cSSSI) caused by gram-positive bacteria, ... for severe abscesses, cellulitis and wound
infections were 96%, 97% and 90%, respectively. Clinical ... effect of oral torezolid in curing severe skin
infections caused by MRSA and other gram-positive ...
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
... therapy was diagnosed with tuberculosis. Serious
infections were reported as follows: 8 in the azathioprine ... to fight infections. There are reports of serious
infections caused by viruses, fungi or bacteria that have ... (TB) and histoplasmosis. Some of these
infections have been fatal. Doctors should monitor closely ...
Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
... the incidence of severe and life-threatening
infections and
infections resulting in death. Leukine also has been ... growth factor approved to reduce the incidence of
infections resulting in early death following induction ...
CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
... the launch of a three-year campaign to reduce
infections among cancer patients. The campaign will provide ... are highly concerned about the impact that
infections have on treatment outcomes. According to a new ... say it is extremely to very important to prevent
infections to achieve successful outcomes in chemotherapy ...
Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
... five years for the treatment of intra-abdominal
infections because of their potent broad-spectrum activity ... organisms.
"Treatment for intra-abdominal
infections is largely empiric," stated Lisa Arias, analyst ... look for in a drug to treat intra-abdominal
infections is its activity against anaerobes."
The new ...
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
... agents that help provide protection against
infections associated with implanted pacemakers and ... time to infection of 52 days, the preliminary
infections rates in the ARR are as follows:
All ... infection
Implant Type implants
infections rate ...
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... serious adverse reactions of Cimzia(R) were
infections (including tuberculosis and histoplasmosis) and ... are at an increased risk for developing serious
infections that may lead to hospitalization or death. Most patients who developed these
infections were taking concomitant immunosuppressants such ...
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
... of tobramycin,
an innovative treatment for
infections of the respiratory tract in patients
with cystic ... as compared
to currently marketed treatments for
infections of the respiratory tract in
patients with cystic ... is granted with respect to treatment of
pulmonary
infections caused by Pseudomonas aeruginosa, a bacterium ...
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
... nasopharyngitis, upper respiratory tract
infections and nausea. Lymphopenia, an expected event based ... 2%).
The overall rate and incidence of
infections in patients treated with Cladribine Tablets and placebo were similar. Herpes zoster
infections were reported in 2.3% of patients treated with ...
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
... products to treat and prevent a wide range of
infections with low chance of developing drug resistance, ... results of a Phase II clinical trial in ear
infections (otitis externa) using NCT. NovaBay expects ... blood cells to treat and prevent a wide range of
infections without causing resistance. NovaBay has internal ...
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
... in complicated skin and skin structure
infections (cSSSI). Delafloxacin successfully completed two ... cSSSI
Complicated skin and skin structure
infections (cSSSI) encompass a wide range of serious
infections involving the deeper soft tissue, including ...
CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
... Efforts Turn the Tide on Antibiotic-Resistant
infections
PRINCETON, N.J., March 23 ... in the proportion of Staphylococcus aureus
infections caused by methicillin-resistant bacteria, ... each hospital's approach to reducing MRSA
infections through PD was different, as is the nature of the ...
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
... a 70 percent decrease in surgical site
infections from 18.4 percent in the control group to 5.6 ... for the treatment of localized, deep tissue
infections and the prevention of surgical site
infections in both hard and soft tissues. GENTAMICIN ...
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
... is one of the most common hospital acquired
infections with up to 500,000 cases reported annually in ... use of Vancocin - Staphylococcus aureus GI
infections - which occur in both the upper and lower GI ... Capsules should be used only to treat or prevent
infections that are proven or strongly suspected to be ...
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
... to be at higher risk of developing sternal wound
infections (SWI); a serious and potentially life-threatening ... for the treatment of localized, deep tissue
infections and the prevention of surgical site
infections in both hard and soft tissues. GENTAMICIN ...
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
... of a wide range of bacterial, fungal, and viral
infections without developing resistance, today announced ... is a group of chronic and common skin
infections that causes significant discomfort and cosmetic ... of 2009 for impetigo, one of the most common skin
infections among children, which produces blisters or sores ...
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
... with complicated intra-abdominal
infections (cIAIs). In 2007,
Novexel estimates that more ... is being developed to treat hospital
infections that
are caused by Gram negative bacteria, ... intra-abdominal infections
include those
infections requiring surgical intervention and which ...
Children and Orthopaedic Surgical Emergencies
... Fractures and
infections of the bone are among most serious injuries to ... ).
"We see a lot more children with
infections of the joints, bones and particularly the soft ... Drexel University College of Medicine.
The
infections usually result from bacteria in the bloodstream, ...
Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
... services research."
Antibiotic-resistant
infections are a growing and serious public health problem, ... in health care settings. While most bacterial
infections can be effectively controlled using existing ... 70 percent of the bacteria that cause health care
infections have resistance to at least one or more ...
10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
... of reducing central-line associated blood stream
infections in hospital intensive care units (ICUs), ... program across the 10 states to help prevent
infections related to the use of central line catheters. ... cases of central line-associated bloodstream
infections occur in hospitals in the United States, leading ...
Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
... 16th
Conference on Retroviruses and Opportunistic
infections (CROI).
"Those with recent HIV
infections who have not yet developed an HIV
antibody ... "The
current method for detection of acute
infections is expensive and labor-
intensive pooled nucleic ...
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
... 16th Conference on Retroviruses and Opportunistic
infections in Montreal.
"We are extremely excited with ... entered the study.
A total of 194 new HIV
infections occurred among study participants over the course ... with HIV/AIDS worldwide are women. Most HIV
infections in women are due to heterosexual intercourse. ...
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
...
The Need for New Means to Fight Anthrax
infections
Two options have been available for the prevention or treatment of anthrax
infections - a vaccine and antibiotics. Both are essential ... anthrax bacteria. It may also prevent and treat
infections by antibiotic-resistant strains of anthrax. ...
Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
... patients with complicated skin and skin structure
infections (cSSSI). The trial, which was conducted in 12 ... of the increasing prevalence of bacterial
infections caused by MRSA in our hospitals and communities ... effective treatments for drug resistant bacterial
infections in the hospital and in the community."
About ...
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
... percent), thrombocytopenia (eight percent),
infections (36 percent), and was stopped early in 65 cases ... (43 percent), hematotoxicity (14 percent) and
infections (29 percent). The median alemtuzumab dose given ...
WARNING: CYTOPENIAS, INFUSION REACTIONS, AND
infections
Cytopenias: Serious, ...
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
... Gram-Positive Pathogens and MRSA in Skin
infections -
NEW HAVEN, Conn., Dec. 8 ... treatment of complicated skin and skin structure
infections (cSSSI). Additionally, when evaluated in vitro ...
About Complicated Skin and Skin Structure
infections (cSSSI)
Complicated skin and skin ...
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
... the incidence of severe and life-threatening
infections and
infections resulting in death.
"We are pleased to ...
WARNING: CYTOPENIAS, INFUSION REACTIONS, AND
infections
Cytopenias: Serious, ...
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
... (ii)The most common
antibiotic used to treat MRSA
infections is vancomycin, but recent evidence
suggests ... for an average
of 94,000 life-threatening
infections and 18,650 deaths each year in the
United ... in development for the treatment of
serious
infections requiring hospitalization caused by ...
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
... patients with complicated urinary tract
infections (cUTIs).
From national databases providing ... is being developed to treat hospital
infections that are
caused by Gram negative bacteria, ... in
confronting the increasing problem of hospital
infections caused by
resistant Gram negative bacteria. The ...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
... in Europe for
the treatment of ocular viral
infections for more than 10 years.
Herpes simplex ... and those with fungal or
mycobacterial
infections of the eye or ocular structures. Prolonged use ... and
increase the development of fungal
infections of the cornea. It is
important to monitor ...
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
... trials that
focused on complicated urinary tract
infections (cUTIs) and pyelonephritis
(2); complicated intra-abdominal
infections (cIAI) (2); nosocomial
pneumonia (NP), including ... for the treatment of
complicated intra-abdominal
infections (cIAI) and complicated urinary tract
infections ...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
... (AEs). Reported
serious adverse reactions were
infections (including tuberculosis) and
malignancies ... receiving TNF
blockers, including CIMZIA.
infections have been reported in patients
receiving CIMZIA ... hematologic abnormalities.
Serious
infections were seen in clinical studies with concurrent use ...
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
... of uncomplicated skin and skin
structure
infections (uSSSI). These results were announced at the ... clinically evaluable patients with confirmed
MRSA
infections with a 95% confidence interval were 100% and ... with uncomplicated
skin and skin structure
infections (uSSSI). The study assessed the efficacy
of a ...